Table 2.

The relative content of the 15 distinctive metabolites in the validation set. Median(IQR)/mean ± SD. *comparison between control tissues and WHO grades I–II gliomas; ^#comparison between the control tissues and WHO grades III–IV gliomas, the p of * and ^# < 0.05. p value in right column means the statistical differences among 3 groups (control, WHO grades I and II and WHO grades III and IV group).

matabolite	Control	WHO grades I and II	WHO grades III and IV	P value
pAp	0.001 (0.000, 0.010)	0.610 (0.503, 0.798)*	0.650 (0.533, 0.743)#	<0.001
Appr > p	0.094 ± 0.019	0.771 ± 0.144*	0.680 ± 0.207#	<0.001
2-Hexaprenyl-6-methoxyphenol	0.048 ± 0.021	0.350 ± 0.096*	0.363 ± 0.126#	<0.001
DG(33:3)	0.110 (0.000, 0.521)	8.121 (5.023, 19.581)*	6.546 (4.714, 8.981)#	<0.001
CE(15:0)	0.218 ± 0.069	1.019 ± 1.127*	0.615 ± 0.209#	0.031
PC(36:1)	110.489 ± 14.283	0.000 ± 0.000*	0.000 ± 0.000#	<0.001
PC(36:3)	0.220 (0.000, 0.341)	6.008 (4.426, 6.610)*	3.019 (2.570, 3.543)#	<0.001
PC(38:6)	2.855 (2.457, 3.748)	3.526 (2.755, 4.448)*	16.551 (15.235, 17.338)#	<0.001
PC(38:4)	0.000 ± 0.000	7.712 ± 2.488*	3.998 ± 2.761#	<0.001
LysoPC(18:0)	0.000 (0.000, 0.003)	0.316 (0.289, 0.426)*	0.396 (0.356, 0.454)#	<0.001
LysoPE(18:3)	0.000 (0.000, 0.002)	0.253 (0.218,0. 374)*	0.203 (0.117, 0.285)#	0.001
LysoPE(20:3)	0.000 (0.000, 0.004)	0.660 (0.556, 0.828)*	0.712 (0.533, 0.881)#	<0.001
LysoPE(18:0)	0.017 ± 0.020	0.741 ± 0.072*	0.716 ± 0.114#	<0.001
Ceramide(d18:1/16:0)	0.019 (0.000, 0.031)	0.785 (0.500, 0.847)*	0.798 (0.639, 0.857)#	<0.001
SM(d18:0/12:0)/C12	0.025 (0.000, 0.102)	8.191 (3.103, 10.808)	6.303 (3.166, 6.832)#	0.009